Latest News-KAZIA THERAPEUTICS LIMITED. Mediaroom_Page

Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer

Planned Enrollment to Increase from 12 to 36 Patients Following Continued Encouraging Safety and To...

2026-05-26 19:30 5862

Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform

SYDNEY, April 15, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), a clinical-stage oncology...

2026-04-15 20:00 6623

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and met...

2026-01-30 21:00 11232

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

SYDNEY, Jan. 27, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical ...

2026-01-27 21:00 10296

Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End

SYDNEY, Jan. 8, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) today announced that its Chi...

2026-01-08 22:00 9544

Kazia Therapeutics Regains Full Nasdaq Listing Compliance

Restoration of Nasdaq compliance follows $50 million institutional financing and reinforces balance...

2025-12-22 21:00 7609

Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+

First patient from TNBC trial demonstrated 76% tumor volume shrinkage with corresponding reductions...

2025-12-10 21:00 7510

Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities

SYDNEY, Dec. 2, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused...

2025-12-02 22:00 5137

Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy

SYDNEY, Nov. 18, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (Nasdaq: KZIA), an oncology-focuse...

2025-11-19 05:15 4429

Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner

SYDNEY, Oct. 27, 2025 /PRNewswire/ -- Kazia Therapeutics Limited ("Kazia" or the "Company") today a...

2025-10-27 19:15 2610

Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program

SYDNEY, Oct. 7, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused...

2025-10-07 20:30 3079

Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy

SYDNEY, Sept. 11, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focus...

2025-09-11 20:00 3671

Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market

SYDNEY, Aug. 1, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused...

2025-08-01 20:00 5635

Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial

SYDNEY, July 9, 2025 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) is pleased to announce preli...

2025-07-09 20:00 4191

Latest News